Celldex Therapeutics, Inc (CLDX) — Analysis Summary
Celldex Therapeutics, Inc (CLDX) has a market cap of $2.31B with year-over-year revenue growth of -78.0%. Net margin stands at -16748.0%. The stock trades at a P/E ratio of -7.7.
Key Takeaways
- Revenue changed -78.0% year-over-year
- Net margin of -16748.0%
- P/E ratio of -7.7
Compared to other companies in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES sector, CLDX posted revenue growth of -78.0% and trades at a P/E of -7.7.
Celldex Therapeutics, Inc (CLDX)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Operating margin at -206220.3% — severe operating losses
Net margin at -190220.9% — losses exceed revenue (possible one-time charges)
Revenue fell 89.8% vs the prior period.
The latest filing shows negative free cash flow.
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
Sector
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Employees
198
Headquarters
HAMPTON, NJ
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.